Joseph Cu
Internal Medicine · San Jose, CANPI 1912086364
Payments from drug & device makers
Across 1,047 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novo Nordisk$2K
- Johnson & Johnson$2K
- Lilly USA, LLC$1K
- Abbott$1K
- Boehringer Ingelheim$1K
- plus $13K from 37 others
What the payments were for
- Food & beverage$23,05098%
- Education$4772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$636
- NUZYRA$600
- FASENRA$531
- BREZTRI$509
- FREESTYLE LIBRE 3$410
- Tirosint$372
- Repatha$265
- PYRUKYND$261
- NEXLETOL$250
- NEXLIZET$250
- NURTEC ODT$245
- AIRSUPRA$237
- Kerendia$235
- DEXCOM G7 GSS (161)$145
- DEXCOM STELO GLUCOSE BIOSENSOR$145
- Vascepa$129
- SOLIQUA 100/33$125
- AIMOVIG$125
- Leqembi$125
- GENERAL PAIN MANAGEMENT$124
How this compares
$23,527 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 197 | $192,844 |
| JardianceEmpagliflozin | 110 | $123,940 |
| KerendiaFinerenone | 103 | $104,126 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 74 | $79,724 |
| EliquisApixaban | 55 | $64,956 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $61,564 |
| Xigduo XrDapaglifloz Propaned/Metformin | 54 | $50,671 |
| RybelsusSemaglutide | 26 | $44,689 |
| TrulicityDulaglutide | 20 | $38,036 |
| SynjardyEmpagliflozin/Metformin Hcl | 43 | $35,242 |
| VascepaIcosapent Ethyl | 37 | $29,958 |
| OzempicSemaglutide | 23 | $28,287 |
| XareltoRivaroxaban | 26 | $26,064 |
| Icosapent Ethyl | 43 | $25,000 |
| JanuviaSitagliptin Phosphate | 21 | $24,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $1,140 | $238,906227 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,974 | $203,109212 claims |
| BayerKerendia | $1,039 | $104,126103 claims |
| Novo NordiskRybelsus, Ozempic | $1,633 | $72,97649 claims |
| PfizerEliquis | $491 | $64,95655 claims |
| GSKTrelegy Ellipta | $942 | $61,56456 claims |
| MerckJanuvia, Janumet | $392 | $46,62942 claims |
| Lilly USA, LLCTrulicity | $1,375 | $38,03620 claims |
| Johnson & JohnsonXarelto | $1,588 | $26,06426 claims |
| NovartisEntresto | $934 | $24,15618 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $977 | $22,86824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Jose
- Peter MazonsonSan Jose$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.